CN112574964A - 用于治疗淀粉状蛋白沉积的方法和组合物 - Google Patents

用于治疗淀粉状蛋白沉积的方法和组合物 Download PDF

Info

Publication number
CN112574964A
CN112574964A CN202011133829.0A CN202011133829A CN112574964A CN 112574964 A CN112574964 A CN 112574964A CN 202011133829 A CN202011133829 A CN 202011133829A CN 112574964 A CN112574964 A CN 112574964A
Authority
CN
China
Prior art keywords
apoe
aav
protein
nucleic acid
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011133829.0A
Other languages
English (en)
Chinese (zh)
Inventor
B·L·戴维森
B·T·海曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
General Hospital Corp
Original Assignee
University of Iowa Research Foundation UIRF
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Iowa Research Foundation UIRF, General Hospital Corp filed Critical University of Iowa Research Foundation UIRF
Publication of CN112574964A publication Critical patent/CN112574964A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202011133829.0A 2012-05-18 2013-03-14 用于治疗淀粉状蛋白沉积的方法和组合物 Pending CN112574964A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648801P 2012-05-18 2012-05-18
US61/648801 2012-05-18
CN201380038140.1A CN104540952A (zh) 2012-05-18 2013-03-14 用于治疗淀粉状蛋白沉积的方法和组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380038140.1A Division CN104540952A (zh) 2012-05-18 2013-03-14 用于治疗淀粉状蛋白沉积的方法和组合物

Publications (1)

Publication Number Publication Date
CN112574964A true CN112574964A (zh) 2021-03-30

Family

ID=49584137

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011133829.0A Pending CN112574964A (zh) 2012-05-18 2013-03-14 用于治疗淀粉状蛋白沉积的方法和组合物
CN201380038140.1A Pending CN104540952A (zh) 2012-05-18 2013-03-14 用于治疗淀粉状蛋白沉积的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380038140.1A Pending CN104540952A (zh) 2012-05-18 2013-03-14 用于治疗淀粉状蛋白沉积的方法和组合物

Country Status (12)

Country Link
US (1) US20150183850A1 (enExample)
EP (1) EP2850195B1 (enExample)
JP (2) JP6469000B2 (enExample)
CN (2) CN112574964A (enExample)
AU (1) AU2013263346B2 (enExample)
BR (1) BR112014028666B1 (enExample)
CA (1) CA2873890C (enExample)
ES (1) ES2786078T3 (enExample)
HK (1) HK1207109A1 (enExample)
IN (1) IN2014KN02672A (enExample)
RU (1) RU2673484C2 (enExample)
WO (1) WO2013172964A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116063405A (zh) * 2022-09-27 2023-05-05 广州译码基因科技有限公司 可提高AAV病毒包装能力的衣壳蛋白突变体MutC及其应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077689A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Modulatory polynucleotides
WO2016196507A1 (en) 2015-05-29 2016-12-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
WO2016198627A1 (en) * 2015-06-12 2016-12-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of alzheimer's disease
EP3444344A4 (en) * 2016-04-14 2020-02-19 TAO Health Life Pharma Co., Ltd. AMYLOSPHEROID TYPE STRUCTURE (ASPD) AND PHARMACEUTICAL COMPOSITION
CA3024448C (en) 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
AU2017306558B2 (en) * 2016-08-03 2024-09-19 University Of South Florida Reelin compositions for treatment of neurological disorders
WO2018045347A1 (en) * 2016-09-02 2018-03-08 Spark Therapeutics, Inc. Methods and vectors for treating cns disorders
EP3309550A1 (en) * 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
KR102709597B1 (ko) 2017-10-03 2024-09-26 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
AU2018346102B2 (en) 2017-10-03 2023-05-11 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
WO2020112802A1 (en) * 2018-11-28 2020-06-04 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative disease
KR20220082050A (ko) * 2019-10-16 2022-06-16 코넬 유니버시티 알츠하이머병에 대한 유전자 요법
KR20230020946A (ko) * 2020-03-31 2023-02-13 누오-베타 파마슈티컬 테크놀로지 (상하이) 씨오., 엘티디. 중수소화 옥소페닐아르신 화합물 및 이의 용도
MX2023006153A (es) * 2020-11-25 2023-07-18 Prevail Therapeutics Inc Terapias genicas para enfermedad neurodegenerativa.
WO2023108507A1 (en) * 2021-12-15 2023-06-22 National Institute Of Biological Sciences, Beijing Recombinant aav vectors and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US6436996B1 (en) * 1997-09-30 2002-08-20 Duke University Modulation of nitric oxide production
US6468524B1 (en) * 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US6855314B1 (en) 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
CN101124328A (zh) * 2004-12-15 2008-02-13 北卡罗来纳查佩尔山大学 嵌合载体
EP1879623B1 (en) * 2005-05-02 2012-10-03 Genzyme Corporation Gene therapy for spinal cord disorders
CN101610793B (zh) * 2006-09-14 2012-10-24 迈德詹尼克斯医疗以色列有限公司 长效药物制剂
PL2154969T3 (pl) * 2007-05-16 2016-04-29 Brigham & Womens Hospital Inc Leczenie synukleinopatii
US9272053B2 (en) * 2010-04-23 2016-03-01 University Of Massachusetts AAV-based treatment of cholesterol-related disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116063405A (zh) * 2022-09-27 2023-05-05 广州译码基因科技有限公司 可提高AAV病毒包装能力的衣壳蛋白突变体MutC及其应用

Also Published As

Publication number Publication date
EP2850195B1 (en) 2020-01-22
BR112014028666A2 (pt) 2017-06-27
IN2014KN02672A (enExample) 2015-05-08
ES2786078T3 (es) 2020-10-08
BR112014028666B1 (pt) 2021-12-07
US20150183850A1 (en) 2015-07-02
AU2013263346B2 (en) 2018-08-23
AU2013263346A1 (en) 2014-12-04
CA2873890C (en) 2022-12-06
CA2873890A1 (en) 2013-11-21
EP2850195A1 (en) 2015-03-25
CN104540952A (zh) 2015-04-22
JP2015520161A (ja) 2015-07-16
HK1207109A1 (en) 2016-01-22
RU2014151218A (ru) 2016-07-10
JP6469000B2 (ja) 2019-02-13
RU2673484C2 (ru) 2018-11-27
WO2013172964A1 (en) 2013-11-21
EP2850195A4 (en) 2015-12-09
JP2019031564A (ja) 2019-02-28

Similar Documents

Publication Publication Date Title
EP2850195B1 (en) Methods and compositions for treating amyloid deposits
JP7610923B2 (ja) Ｃｎｓ障害を治療するための方法及びベクター
EP3071240B1 (en) Method for monitoring efficacy of treatment of alzheimer's disease with an apoe isoform
US20240325570A1 (en) Treating diseases and improving nucleic acid delivery
EP4410988A1 (en) An aav2-vector variant for targeted transfer of genes
US20240115736A1 (en) Methods and materials for treating tdp-43 proteinopathies
BR112016011258B1 (pt) Métodos e composiçôes para o tratamento de depósitos de amiloide
HK1229258A1 (en) Method for monitoring efficacy of treatment of alzheimer's disease with an apoe isoform
HK1229258B (en) Method for monitoring efficacy of treatment of alzheimer's disease with an apoe isoform
JP2023548632A (ja) アルツハイマー病の処置のための組成物および方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination